Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $22 | $46 | $35 | $91 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $3 | $4 | $21 |
| Total Curr. Assets | $24 | $49 | $39 | $112 |
| Property Plant & Equip (Net) | $0 | $0 | $1 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $1 |
| Total NC Assets | $0 | $0 | $1 | $4 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $24 | $49 | $41 | $116 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $1 | $3 |
| Short-Term Debt | $0 | $0 | $1 | $11 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $4 | $10 |
| Other Curr. Liab. | $3 | $7 | $23 | $80 |
| Total Curr. Liab. | $4 | $7 | $25 | $94 |
| LT Debt | $0 | $0 | $0 | $27 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $18 | $0 | $18 | $21 |
| Total NC Liab. | $18 | $18 | $18 | $48 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22 | $25 | $43 | $142 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $18 | $18 | $21 |
| Common Stock | $0 | $0 | $0 | $1 |
| Retained Earnings | -$575 | -$550 | -$541 | -$533 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $578 | $575 | $520 | $485 |
| Total Equity | $2 | $24 | -$2 | -$26 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $24 | $49 | $41 | $116 |
| Net Debt | -$22 | -$46 | -$34 | -$53 |